

SPECIALTY GUIDELINE MANAGEMENT

Cytogam (Cytomegalovirus Immune Globulin Intravenous [Human])

POLICY

A. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cytogam is indicated for the prophylaxis of cytomegalovirus (CMV) disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs (other than kidney) from CMV seropositive donors into seronegative recipients, prophylactic Cytogam should be considered in combination with ganciclovir.

Compendial Uses

- Treatment of CMV pneumonitis in bone marrow transplant recipients
- Treatment or prevention of congenital CMV infection

All other indications are considered experimental/investigational and are not a covered benefit.

B. EXCLUSIONS

- History of a prior severe reaction associated with the administration of Cytogam or any other human immunoglobulin preparations
- Persons with selective IgA deficiency with antibodies to IgA and a history of anaphylactic reactions to human immune globulin preparations

C. CRITERIA FOR APPROVAL

1. **CMV prophylaxis in solid organ transplant recipients**

Authorization of 12 months may be granted to members who are solid organ transplant recipients (e.g., heart, liver, lung) and are prescribed Cytogam for the prevention of CMV disease.

2. **CMV pneumonitis in bone marrow transplant recipients**

Authorization of 12 months may be granted to members who are bone marrow transplant recipients and are prescribed Cytogam in combination with an antiretroviral medication for the treatment of CMV pneumonitis.

3. **Congenital CMV infection**

Authorization of one dose may be granted to members who are prescribed Cytogam for the treatment of CMV infection during pregnancy.

D. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

E. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

REFERENCES

1. Cytogam [package insert]. Kankakee, IL: CSL Behring LLC; August 2012.
2. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado. Available at <http://www.micromedexsolutions.com>. Accessed December 17, 2014.
3. AHFS Drug Information. <http://online.lexi.com/lco>. Accessed December 17, 2014.
4. Bratanow NC, Ash RC, Turner PA, et al. Successful treatment of serious cytomegalovirus disease with 9 (1,3-dihydroxy-2-propoxymethyl)-guanine and intravenous immunoglobulin in bone marrow transplant patients. *Exp Hematol.* 1987;15:541.
5. Ljungman P, Englehard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group. *Clin Infect Dis.* 1992;14:831.
6. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. *Ann Intern Med.* 1988;109:783.
7. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. *Transplantation.* 1988;46:905.
8. Kotton CN, Kumar D, Caliendo AM, et al for the Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. *Transplantation.* 2010;89(7):779-795.
9. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. *Clin Transplant.* 2008;22(1):89-97.
10. Costanzo MR, Costanzo MR, Dipchand A, et al for the International Society of Heart and Lung Transplantation. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant.* 2010;29(8):914-956.
11. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. *Clin Infect Dis.* 2012;55(4):497-503